A 60-minute test meal C-peptide level was found to successfully predict switching from insulin therapy to liraglutide monotherapy among 69 patients with type 2 diabetes who were on a low 1.9-unit average daily insulin dose [27]. The gene discussed is INS; the disease is type 2 diabetes mellitus.